{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:09:21Z","timestamp":1792786161620,"version":"4.5.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases","award":["T35DK104689"],"award-info":[{"award-number":["T35DK104689"]}],"id":[{"id":"https:\/\/ror.org\/00adh9b73","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate the associations among peripregnancy glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure with hypertensive disorders of pregnancy (HDP) and gestational weight gain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study that included patients who delivered between 2014 and 2024 and had GLP-1RA exposure up to 1 year before pregnancy. Participants were identified through electronic medical record query with manual medical record abstraction to confirm exposure stop dates. Exposure to GLP-1RAs was classified by indication: pregestational diabetes mellitus or weight management. Unexposed control groups for each indication cohort were identified from an existing institutional data repository from 2021 to 2022. Demographic and clinical characteristics and obstetric outcomes were compared. The two primary outcomes were gestational weight gain and HDP. Gestational weight gain was quantified as below, meeting, or exceeding recommended gestational weight gain. Crude odds ratios and adjusted odds ratios (aORs) were estimated using multivariable modeling. Regression analysis was stratified as GLP-1RA exposure prepregnancy only or during pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>We included 243 patients who were exposed to GLP-1RA up to 1 year before pregnancy, with 65.4% having evidence of use during pregnancy. Overall, 103 (42.4%) patients used GLP-1RA for pregestational diabetes and 140 (57.6%) patients used it for weight management, compared with 175 unexposed patients in the pregestational diabetes control group and 200 unexposed patients in the weight-management control group (body mass index [BMI] 30\u201339.9: n=100; BMI 40 or higher: n=100). Exposure to GLP-1RAs was not associated with gestational weight gain in the pregestational diabetes cohort but was associated with decreased odds of gestational weight gain below recommendations (aOR 0.37, 95% CI, 0.18\u20130.78) in the weight-management cohort. Exposure to GLP-1RAs was not associated with HDP when compared with unexposed individuals with pregestational diabetes (aOR 0.72, 95% CI, 0.42\u20131.25) or with unexposed individuals who were undergoing weight management (aOR 0.83, 95% CI, 0.45\u20131.52).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>In individuals undergoing weight management, peripregnancy GLP-1RA exposure was associated with decreased odds of gestational weight gain below recommendations, which may reflect rebound weight gain after cessation. Peripregnancy GLP-1RA exposure was not associated with developing HDP in either the pregestational diabetes or weight-management cohort. Additional studies are needed to guide GLP-1RA use in pregnancy and to better elucidate any risks of exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000005995","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T17:00:28Z","timestamp":1751562028000},"page":"293-302","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["Gestational Weight Gain and Hypertensive Disorders of Pregnancy With Prepregnancy and Early Pregnancy Glucagon-Like Peptide-1 Receptor Agonist Exposure"],"prefix":"10.1097","volume":"147","author":[{"given":"Nishita","family":"Pondugula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer F.","family":"Culhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbet S.","family":"Lundsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey A.","family":"Merriam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"R1-20260930","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1\u20137 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab"},{"key":"R2-20260930","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2024.04.041","article-title":"Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"222","author":"Moiz","year":"2024","journal-title":"Am J Cardiol"},{"key":"R3-20260930","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/ijms25031909","article-title":"Infertility improvement after medical weight loss in women and men: a review of the literature","volume":"25","author":"Pavli","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R4-20260930","doi-asserted-by":"crossref","first-page":"e2695","DOI":"10.1210\/clinem\/dgaa285","article-title":"Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists","volume":"105","author":"Cena","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R5-20260930","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/MED.0000000000000835","article-title":"Glucagon-like peptide-1 receptor agonists and safety in the preconception period","volume":"30","author":"Minis","year":"2023","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R6-20260930","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12902-023-01500-5","article-title":"Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Endocr Disord"},{"key":"R7-20260930","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajog.2024.08.024","article-title":"Glucagon-like peptide-1 receptor agonist use in pregnancy: a review","volume":"232","author":"Drummond","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"R8-20260930","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","article-title":"Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy","volume":"184","author":"Cesta","year":"2024","journal-title":"JAMA Int Med"},{"key":"R9-20260930","doi-asserted-by":"crossref","first-page":"e083550","DOI":"10.1136\/bmjopen-2023-083550","article-title":"Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six teratology information services","volume":"14","author":"Dao","year":"2024","journal-title":"BMJ Open"},{"key":"R12-20260930","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"R13-20260930","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"R14-20260930","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s12325-014-0164-2","article-title":"Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials","volume":"31","author":"Du","year":"2014","journal-title":"Adv Ther"},{"key":"R15-20260930","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"key":"R16-20260930","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3390\/nu11071667","article-title":"Weight loss and hypertension in obese subjects","volume":"11","author":"Fantin","year":"2019","journal-title":"Nutrients"},{"key":"R17-20260930","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/jch.14236","article-title":"Non\u2010pharmacological management of hypertension","volume":"23","author":"Verma","year":"2021","journal-title":"J Clin Hypertens"},{"key":"R18-20260930","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41430-021-00902-9","article-title":"Preconceptional maternal weight loss and hypertensive disorders in pregnancy: a systematic review and meta-analysis","volume":"75","author":"Schenkelaars","year":"2021","journal-title":"Eur J Clin Nutr"},{"key":"R20-20260930","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/jp.2016.149","article-title":"Gestational weight gain and preterm birth: disparities in adolescent pregnancies","volume":"36","author":"Woolfolk","year":"2016","journal-title":"J Perinatol"},{"key":"R21-20260930","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 222. American College of Obstetricians and Gynecologists","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R22-20260930","doi-asserted-by":"crossref","first-page":"e20190076","DOI":"10.1542\/peds.2019-0076","article-title":"A 2017 US reference for singleton birth weight percentiles using obstetric estimates of gestation","volume":"144","author":"Aris","year":"2019","journal-title":"Pediatrics"},{"key":"R23-20260930","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/AOG.0000000000001711","article-title":"Management of preterm labor. Practice Bulletin No. 171. American College of Obstetricians and Gynecologists","volume":"128","year":"2016","journal-title":"Obstet Gynecol"},{"key":"R24-20260930","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diab Obes Metab"},{"key":"R25-20260930","doi-asserted-by":"crossref","first-page":"8056440","DOI":"10.1155\/2024\/8056440","article-title":"A comprehensive review on weight gain following discontinuation of glucagon-like peptide-1 receptor agonists for obesity","volume":"2024","author":"Abdullah Bin Ahmed","year":"2024","journal-title":"J Obes"},{"key":"R26-20260930","doi-asserted-by":"crossref","first-page":"101168","DOI":"10.1016\/j.preghy.2024.101168","article-title":"Circulating concentrations of pro-inflammatory cytokines in preeclampsia with varying disease severity","volume":"38","author":"Palm","year":"2024","journal-title":"Pregnancy Hypertens"},{"key":"R27-20260930","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s43032-020-00258-8","article-title":"Downregulation of cAMP-dependent protein kinase Inhibitor-b promotes preeclampsia by decreasing phosphorylated akt","volume":"28","author":"Liu","year":"2021","journal-title":"Reprod Sci"},{"key":"R28-20260930","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00404-022-06700-3","article-title":"Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT","volume":"306","author":"Li","year":"2022","journal-title":"Arch Gynecol Obstet"},{"key":"R29-20260930","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/01.AOG.0000425668.87506.4c","article-title":"Weight gain during pregnancy. Committee Opinion No. 548. American College of Obstetricians and Gynecologists","volume":"121","year":"2013","journal-title":"Obstet Gynecol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:00:39Z","timestamp":1790780439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005995","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"2025-03-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}